As you know, but I have not stated succintly on the board, I guess differently. If they announce only one 'new' thing in, say, a 1 year period then I think the price might pop - say to 30. But then they get taken out at below any reasonable valuation of their market cap. Might be for a nice premium to 30, might even just barely make it to "multibagger" - but might not. But certainly no Dendreon. OTOH if they can pull off 2 or 3 no-overhang announcements (e.g. launch of Copaxone without litigation risk, deal in their unique form of LMWH, and partnership for generic biologics while FDA clarifies that there is a substitution pathway for biologics) then I think they are likely to get to a reasonable recognition of their value. Might still get taken out - but at least at a reasonable value.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.